Anika Therapeutics (ANIK) Income from Continuing Operations (2010 - 2026)

Anika Therapeutics (ANIK) has 17 years of Income from Continuing Operations data on file, last reported at 5056000.0 in Q1 2026.

• On a quarterly basis, Income from Continuing Operations fell 27.39% year-over-year to 5056000.0 in Q1 2026; TTM through Mar 2026 was 11005000.0, a 9.46% increase from a year earlier, with the FY2025 full-year figure at 9918000.0, up 2.21% from the prior year.
• Income from Continuing Operations for Q1 2026 stood at 5056000.0, down from 1853000.0 in the prior quarter.
• Over the last five years, Income from Continuing Operations for ANIK reached as high as 15493000.0 in Q4 2023 and fell as low as 10350000.0 in Q1 2023.
• Historically, Income from Continuing Operations has averaged 1592823.53 across 5 years, with a median of 2933000.0 in 2022.
• On a YoY basis, Income from Continuing Operations climbed as much as 213.4% in 2022 and fell as far as 856.34% in 2022.
• Year by year, Income from Continuing Operations stood at 12155000.0 in 2022, then rose by 27.46% to 15493000.0 in 2023, then sank by 124.53% to 3800000.0 in 2024, then soared by 148.76% to 1853000.0 in 2025, then tumbled by 372.85% to 5056000.0 in 2026.
• Per Business Quant data, the three most recent Income from Continuing Operations figures were 5056000.0 in Q1 2026, 1853000.0 in Q4 2025, and 3136000.0 in Q3 2025.